Clinical features and risk factors of patients with fatty liver in Guangzhou area

Table 4 Comparison of laboratory abnormalities among AFL, NAFL and control groups (%)

Biochemical Index	AFL group(n = 28)	NAFL group(n = 301)	Control group(n = 163)
TG (≥ 1.7 mmol/L)	2(7.1)a	169(56.2)c	27(17.7)
CHOL (≥ 5.2 mmol/L)	2(7.1)a	148(49.2)c	35(22.9)
HDL-C ( ≤ 1.0 mmol/L)	9(32.1)a	35(11.6)	27(17.7)
LDL-C (≥ 2.6 mmol/L)	12(42.9)a	214(71.1)	97(63.4)
Apo AI ( ≤ 1.2 mmol/L)	13(46.4)	118(39.2)	45(29.4)
Apo B (≥ 1.1 mmol/L)	4(14.3)ac	149(49.5)e	53(34.6)
UA (≥ 452 mg/dL)	5(17.9)	89(29.6)e	18(11.8)
AST (≥ 40 U)	12(42.9)ac	51(16.9)	24(15.7)
ALT (≥ 40 U)	10(35.7)c	87(28.9)e	26(17.0)
AST/ALT ( < 1)	11(39.3)c	168(55.8)e	31(20.3)
(≥ 2)	5(17.9)a	15(5.0)e	40(26.1)
ALB ( ≤ 35 g/L)	3(10.7)	9(3.0)	7(4.6)
GLB (≥ 30 g/L)	3(10.7)	32(10.6)	20(13.1)
A/G ( ≤ 1.5)	7(25.0)	64(21.3)	31(20.3)
GGT (≥ 50 U/L)	10(35.7)	95(31.6)e	30(19.6)
TBIL (≥ 17.1 μmol/L)	6(21.4)	50(16.6)	30(19.6)

^aP < 0.05, vs NAFL group;

^cP < 0.05, vs control group;

^eP < 0.05, vs control group.